- Application deadline
- Not stated: check the official notice
- Stipend / salary
- As per norms
- Qualifications mentioned
- Bachelor's (BSc/BTech/BPharm), NET/GATE qualified
- Posted
- 25 May 2026 · Government
About this position
_______________________________________________________________________________________________________ Advertisement No. : NIBMG/ ACAD/PROJECT RECT./2026-27/ 058 Date: 25-05-2026 Position available BRIC-National Institute of Biomedical Genomics (NIBMG) Kalyani is an Institute of Government of India, Ministry of Science & Technology, Department of Biotechnology. The Institute has created the necessary physical infrastructure and critical platform technologies to support research, translation and training in biomedical genomics. Applications are invited for the position of Project Linked Person for extramural project to be executed by the BRIC-National institute of Biomedical Genomics, Kalyani. Selected applicants will be appointed initially for one year. The tenure of appointment may be extended depending on performance and availability of funds. Project Name: Development of a chip to predict steroid responsiveness in children with idiopathic nephrotic syndrome: A global whole transcriptomics (IncRNA-miRNA-mRNA network) based approach. Principal Investigator’s name: Dr. Kaushik Das Research Description: Nephrotic syndrome (NS) is a prevalent kidney disease in children, with an incidence of 2-7 per 100,000 in a year. Most children respond well to steroid treatments, however there are frequent relapses, making it essential to predict responses to corticosteroids for better prognoses. At present, analysis of common diagnostic markers such as serum albumin and proteinuria is insufficient due to the disease's complexity and varying patient responses. While past studies primarily focus on miRNAs in Chinese populations, this project aims to develop a chip that utilizes transcriptomic signatures to predict steroid responsiveness in children with NS. The plan is to conduct a global RNA sequencing to identify key lncRNA-miRNA-mRNA expression signatures linked to disease progression and treatment response, ultimately fostering personalized therapy and improving disease management.